Tibet Rhodiola Pharmaceutical Holding Co. (SHA:600211)

Market Cap	13.45B +15.8%
Revenue (ttm)	2.72B -7.5%
Net Income	981.20M +33.1%
EPS	3.04 +32.9%
Shares Out	322.32M
PE Ratio	13.73
Forward PE	n/a
Dividend	1.87 (4.48%)
Ex-Dividend Date	Sep 1, 2025

Volume	1,397,906
Average Volume	2,972,591
Open	42.09
Previous Close	41.74
Day's Range	41.60 - 42.19
52-Week Range	34.60 - 57.98
Beta	0.40
RSI	38.54
Earnings Date	Mar 13, 2026

About SHA:600211

Tibet Rhodiola Pharmaceutical Holding Co. manufactures pharmaceuticals in China and internationally. The company offers biological products, Tibetan medicine, Chinese medicine, and chemical medicine products. It also provides capsules, biological preparations, granules, and film-coating agents for cardiovascular, cerebrovascular, hepatobiliary, sprains and contusions, rheumatism, rheumatoid arthritis, colds, and other fields. The company was founded in 1999 and is based in Lhasa, China.

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1999
• Employees: 596
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 600211

Financial Performance

In 2024, SHA:600211's revenue was 2.81 billion, a decrease of -10.45% compared to the previous year's 3.13 billion. Earnings were 1.05 billion, an increase of 31.26%.